ArticleInternational journal of oncology2014
Motility of select ovarian cancer cell lines: effect of extra-cellular matrix proteins and the involvement of PAK2.
Article in International journal of oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 37 citations in OpenAlex.
- Analysis of FNDC1 as a diagnostic marker and potential therapeutic target for ovarian serous cancer.BMC cancer · 2025Article
- Article
- EarlyFrontiers in oncology · 2024Article
- Molecular mechanisms of pancreatic cancer liver metastasis: the role of PAK2.Frontiers in immunology · 2024Article
- Molecular mechanisms of microRNA-216a during tumor progression.Cancer cell international · 2023Review
- The metastatic capacity of high-grade serous ovarian cancer cells changes along disease progression: inhibition by mifepristone.Cancer cell international · 2022Article
- A Novel and Validated 8-Pyroptosis-Related Genes Based Risk Prediction Model for Diffuse Large B Cell Lymphoma.Biomolecules · 2022Article
- Injectable three-dimensional tumor microenvironments to study mechanobiology in ovarian cancer.Acta biomaterialia · 2022Article
- Network Analysis Identifies Phase Transitions for Tumor With Interacting Cells.Frontiers in physiology · 2022Article
- Personalized models of heterogeneous 3D epithelial tumor microenvironments: Ovarian cancer as a model.Acta biomaterialia · 2021Review
- Extracellular Matrix: A Treasure Trove in Ovarian Cancer Dissemination and Chemotherapeutic Resistance.Cureus · 2021Review
- STARD4 promotes breast cancer cell malignancy.Oncology reports · 2020Article
- miR-206 as a prognostic and sensitivity biomarker for platinum chemotherapy in epithelial ovarian cancer.Cancer cell international · 2020Article
- Migration dynamics of ovarian epithelial cells on micro-fabricated image-based models of normal and malignant stroma.Acta biomaterialia · 2019Article
- P21 activated kinase 2 promotes pancreatic cancer growth and metastasis.Oncology letters · 2019Article
- Distinct molecular pathways in ovarian endometrioid adenocarcinoma with concurrent endometriosis.International journal of cancer · 2018Article
- Regulating Cdc42 and Its Signaling Pathways in Cancer: Small Molecules and MicroRNA as New Treatment Candidates.Molecules (Basel, Switzerland) · 2018Review
- Expansion of BCR/ABL1British journal of haematology · 2017Article
- Nerve growth factor modulates the tumor cells migration in ovarian cancer through the WNT/β-catenin pathway.Oncotarget · 2016Article
- PAK2 promotes migration and proliferation of salivary gland adenoid cystic carcinoma.American journal of translational research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The interaction between tumor cells and extracellular matrix (ECM) proteins influences cell migration and the invasive behavior of cancer cells. In this study, we provide experimental evidence that collagen I and fibronectin affect ovarian cancer cell migration. In vitro wound healing assays and transwell migration assays were used to measure both total wound healing and directionality of individually migrating OV2008 and C13 ovarian cancer cells on glass, collagen I and fibronectin. Involvement of p21‑activated kinase 2 (Pak2) in the motility of these cell lines was investigated using a chemical inhibitor as well as siRNA transfection. Culturing ovarian cancer cells on collagen type I (COLL) increased the migratory ability of OV2008 and C13 cells by increasing the directional migration of cells. In contrast, fibronectin (FN) decreased the migratory ability of OV2008 cells by reducing their ability to migrate directionally. When both cell lines are cultured on COLL and treated with increasing concentrations of a PAK inhibitor (IPA-3), there is a dose-dependent response such that there is a decrease in migration with an increase in inhibitor concentration. Further experiments utilizing PAK2 knockdown via siRNA transfection demonstrated significantly reduced migration of OV2008 cells on COLL as compared to those receiving control siRNA. In conclusion, our results indicate that FN and COLL affect the motility of the selected ovarian cancer cells lines and the effect of COLL is likely mediated, at least in part, by PAK2. A better understanding of the molecular events that contribute to tumor invasion and metastasis is crucial for developing novel treatment strategies to improve the long-term survival of women with ovarian cancer. As PAK2 is involved in motility, it should be further explored as a pro-metastatic gene in ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.